



# **King's Research Portal**

DOI: 10.1002/stem.1968

Document Version Publisher's PDF, also known as Version of record

Link to publication record in King's Research Portal

Citation for published version (APA):

Murray, A., Letourneau, A., Canzonetta, C., Stathaki, E., Gimelli, S., Sloan-Bena, F., Abrehart, R., Goh, P., Lim, S., Baldo, C., Dagna-Bricarelli, F., Hannan, S., Mortensen, M., Ballard, D., Syndercombe Court, D., Fusaki, N., Hasegawa, M., Smart, T. G., Bishop, C., ... Nizetic, D. (2015). Brief report: Isogenic induced pluripotent stem cell lines from an adult with mosaic down syndrome model accelerated neuronal ageing and neurodegeneration. *Stem cells (Dayton, Ohio)*, *33*(6), 2077-2084. https://doi.org/10.1002/stem.1968

### Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

#### General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
You may not further distribute the material or use it for any profit-making activity or commercial gain
You may freely distribute the URL identifying the publication in the Research Portal

#### Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



# EMBRYONIC STEM CELLS/INDUCED PLURIPOTENT STEM CELLS

<sup>a</sup>The Blizard Institute, Barts and The London School of Medicine and <sup>I</sup>Stem Cell Laboratory, National Centre for Bowel Research and Surgical Innovation, Queen Mary University of London, London, United Kingdom; <sup>b</sup>The LonDownS Consortium, Wellcome Trust, London. United Kingdom: <sup>c</sup>Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland; <sup>d</sup>Service of Genetic Medicine, University Geneva Hospitals, Geneva, Switzerland; <sup>e</sup>Lee Kong Chian School of Medicine. Nanyang Technological University, Singapore, Singapore; <sup>f</sup>Human Genetics Laboratory, Galliera Hospital. Genoa. Italy: <sup>g</sup>Liguria Department of Genetics. Genoa. Italv: <sup>h</sup>Department of Neuroscience, Physiology and Pharmacology, University College London, London. United Kingdom: Department of Forensic and Analytical Science, King's College, London, United Kingdom; <sup>j</sup>Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Saitama, Japan; <sup>k</sup>DNAVEC Corporation, Ibaraki, Tokyo, Japan <sup>†</sup>deceased

Correspondence: Dean Nizetic, M.D. Ph.D., Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Proteos Building, Level 4, 61 Biopolis Drive, iopolis, Singapore 138673, Singapore. Telephone: +65-6778-4728; Fax: +65–6778-5824; e-mail: d. nizetic@ntu.edu.sg or Jurgen Groet, Ph.D., The Blizard Institute, Barts & The London School of Medicine, Blizard Building, 4 Newark Street, London E1 2AT, United Kingdom. Telephone: +442078822271; Fax: +442078822183;e-mail: j.groet@qmul.ac.uk

Received October 12, 2014; accepted for publication January 17, 2015; first published online in STEM CELLS *Express* February 19, 2015.

© AlphaMed Press 1066-5099/2014/\$30.00/0

http://dx.doi.org/ 10.1002/stem.1968

# Brief Report: Isogenic Induced Pluripotent Stem Cell Lines From an Adult With Mosaic Down Syndrome Model Accelerated Neuronal Ageing and Neurodegeneration

Aoife Murray,<sup>a,b</sup> Audrey Letourneau,<sup>c</sup> Claudia Canzonetta,<sup>a</sup> Elisavet Stathaki,<sup>d</sup> Stefania Gimelli,<sup>d</sup> Frederique Sloan-Bena,<sup>d</sup> Robert Abrehart,<sup>a</sup> Pollyanna Goh,<sup>a,b</sup> Shuhui Lim,<sup>e</sup> Chiara Baldo,<sup>f</sup> Franca Dagna-Bricarelli,<sup>g†</sup> Saad Hannan,<sup>h</sup> Martin Mortensen,<sup>h</sup> David Ballard,<sup>i</sup> Denise Syndercombe Court,<sup>i</sup> Noemi Fusaki,<sup>j</sup> Mamoru Hasegawa,<sup>k</sup> Trevor G. Smart,<sup>h</sup> Cleo Bishop,<sup>a</sup> Stylianos E. Antonarakis,<sup>c</sup> Jürgen Groet,<sup>a,b,I</sup> Dean Nizetic<sup>a,b,e</sup>

Key Words. Down syndrome • Neurodegeneration • Neurogenesis • Neuronal differentiation

## Abstract

Trisomy 21 (T21), Down Syndrome (DS) is the most common genetic cause of dementia and intellectual disability. Modeling DS is beginning to yield pharmaceutical therapeutic interventions for amelioration of intellectual disability, which are currently being tested in clinical trials. DS is also a unique genetic system for investigation of pathological and protective mechanisms for accelerated ageing, neurodegeneration, dementia, cancer, and other important common diseases. New drugs could be identified and disease mechanisms better understood by establishment of well-controlled cell model systems. We have developed a first nonintegrationreprogrammed isogenic human induced pluripotent stem cell (iPSC) model of DS by reprogramming the skin fibroblasts from an adult individual with constitutional mosaicism for DS and separately cloning multiple isogenic T21 and euploid (D21) iPSC lines. Our model shows a very low number of reprogramming rearrangements as assessed by a high-resolution whole genome CGH-array hybridization, and it reproduces several cellular pathologies seen in primary human DS cells, as assessed by automated high-content microscopic analysis. Early differentiation shows an imbalance of the lineage-specific stem/progenitor cell compartments: T21 causes slower proliferation of neural and faster expansion of hematopoietic lineage. T21 iPSC-derived neurons show increased production of amyloid peptide-containing material, a decrease in mitochondrial membrane potential, and an increased number and abnormal appearance of mitochondria. Finally, T21-derived neurons show significantly higher number of DNA double-strand breaks than isogenic D21 controls. Our fully isogenic system therefore opens possibilities for modeling mechanisms of developmental, accelerated ageing, and neurodegenerative pathologies caused by T21. STEM CELLS 2015;33:2077-2084

### INTRODUCTION

Trisomy 21 (T21), Down Syndrome (DS) is the most common genetic cause of intellectual disability and dementia with rising global prevalence [1]. Several phenotypes have been observed at molecular and cellular levels that reproduce in primary tissues from human individuals with T21. Some of these cellular phenotypes directly map onto clinical components of DS; these include intellectual disability, defects in cognitive development and agerelated cognitive decline, Alzheimer's disease-like dementia, epilepsy, congenital heart defect, childhood leukemia, and others [2–12]. Modeling DS is beginning to yield pharmaceu

tical therapeutic interventions for amelioration of intellectual disability which are currently being tested in clinical trials. New drugs could be identified by high throughput screening of chemical libraries using cellular assays, and therefore well-controlled cellular model systems are required. In order to eliminate effects of wide phenotypic differences among individuals with DS, the requirement for many experimental purposes has become the use of an isogenic induced pluripotent stem cell (iPSC) model for DS, where the sole difference between iPSC lines is the presence of the third chromosome 21.

Several recent iPSC models of DS have been developed. All of these (with one

exception) used integrational reprogramming. All of these reprogrammed cells were derived from fetal, neonatal, or 1 year old infant DS; actually, three studies [13-15] used the same iPSC lines as a starting point [16]. Some of these studies report defects in neural progenitor cell (NPC) proliferation [17], neurogenesis [13], gliogenesis, and neurite outgrowth [18], others defects in synaptic morphology and function, mitochondrial dysfunction [19], and increased amyloid deposition [15]. Other models show increased propensity to generate hematopoietic precursors and increased multilineage myeloid hematopoiesis potential [14, 20]. Most of these results have been generated on nonisogenic comparisons, with isogenic lines either serendipitously generated in cell culture [14, 19] or using an ingenious but with complex and laborious approach to silence the third chromosome 21 [13, 21]. In some cases, nonisogenic lines were pooled with one isogenic line [14, 19]. In one study, a unique case of heterokaryotypic twin fetal cells was exploited [17]. None of these papers reported a genome-wide high-resolution arraycomparative genomic hybridization (aCGH) analysis of the resulting iPSCs for the rigorous measurement of the artificial copy-number rearrangements known to frequently occur during the reprogramming process.

Here we present the first iPSC DS model which is both nonintegrationally reprogrammed and fully isogenic and the first derived from an adult individual with DS which is a constitutional mosaic. Furthermore, we verify the high level of genome integrity of the resulting iPSCs by showing a very low number of reprogramming rearrangements as assessed by a high-resolution whole genome aCGH, and we make entirely isogenic comparisons of three trisomic and three disomic iPSC lines derived from this model. This approach minimizes the influence of any copy number fluctuations additional to T21 and eliminates genotypic difference noise, allowing the "clean" detection of T21-causing effects. Our model reproduces several T21 cellular pathologies seen in primary human DS cells but hitherto not reported in iPSC models, such as abnormalities in mitochondrial number and size and an increase in DNA double-strand breaks in neurons.

#### MATERIALS AND METHODS

Detailed methods are shown in Supporting Information online.

## RESULTS

We generated the iPSCs by nonintegration reprogramming using temperature-sensitive Sendai virus [22] from primary skin fibroblasts from a young adult diagnosed with constitutional mosaicism for DS (strategy illustrated in Supporting Information Fig. S1). We isolated individual clones (labeled as C[number]), expanded them, and confirmed that they tested positive for alkaline-phosphatase expression, and the presence of markers of pluripotency (Fig. 1A). The Sendai virus was efficiently removed after 7–10 passages (Fig. 1B). Demethylation of the endogenous *NANOG* promoter in the iPSCs, compared to the parental skin fibroblasts, was established via bisulfite sequencing (Fig. 1C). Individual clones were analyzed by rigorous whole-genome microsatellite DNA fingerprinting, which established the presence of clones with T21, and euploid genome (D21), which are otherwise isogenic (Fig. 1D). In a preliminary RNA-seq experiment, the isogenic iPSCs show an expected increase in transcript levels for the majority of HSA21 genes (not shown). The genome integrity of the resulting iPSCs is of a high level, as was assessed by highresolution, whole genome aCGH (Supporting Information Fig. S2). The supernumerary HSA21 is intact and complete in both analyzed trisomic lines (T21C5 and T21C6), and T21 is stable for at least 17-19 passages, which is as far as we tested for the presence of T21 (Supporting Information Fig. S2A). After filtering out the copy number variations (CNVs) that occur commonly in healthy individuals (using comparison to the Database of Genomic Variation) we made an in silico comparison with the published survey of genome-rearrangement artefacts in iPSC generated by conventional integrationreprogramming [23]. Selecting only events at the same aCGH resolution and the same passage number as in our study, we detected a significantly lower number of uncommon CNVs, affecting a significantly lower number of genes in our lines, relative to those generated by classic integrational reprogramming methods (Supporting Information Fig. S2B, S2C). In compliance with international guidelines for iPSC nomenclature [24] we name these iPSCs: NIZEDSM1iD21-C3, -C7, and -C9 for the disomic lines, respectively, and NIZEDSM1iT21-C5, -C6, -C13 for the trisomic lines, respectively (henceforward abbreviated to D21C3, D21C7, D21C9, T21C5, T21C6, and T21C13). Microsatellite DNA fingerprinting was repeated at later passages and confirmed that trisomy 21 is retained through routine passaging (Supporting Information Fig. S2D). The isogenic DS iPSC clones can differentiate into cell lineages of all three embryonic layers both in vitro and in vivo (Supporting Information Fig. S3).

After 45 days in culture, using neuronal differentiation via neuro embryoid body (NEB) protocol (Supporting Information Methods), both disomic and trisomic neuronal differentiation cultures were able to produce mature looking neurons expressing  $\beta$ III-tubulin, the inhibitory neurotransmitter GABA, as well as presynaptic and postsynaptic markers of excitatory synapses, PSD95 and VGlut (Supporting Information Fig. S4A, S4B, respectively). In order to accelerate neuronal differentiation and improve yields, we applied a directed neuronal differentiation protocol using dual SMAD inhibition (Noggin and SB431542), combined with stimulation of retinoid signaling and the addition of the Sonic Hedgehog agonist purmorphamine [25]. Both trisomic and disomic lines were able to produce electrophysiologically active neurons (Supporting Information Fig. S4C) that supported spontaneous action potential firing and functional whole-cell current responses to saturating concentrations of externally applied GABA and glycine, observed in neurons from both D21C3 (at 28 days) and T21C5 lines (at 40 days). In order to gain an approximate estimate of the proportion of neurons likely to fire spontaneous action potentials, we used Ca<sup>2+</sup> imaging and observed multiple Ca<sup>2+</sup> transients, which would be indicative of regenerative spontaneous activity in accord with the firing of spontaneous action potentials (Supporting Information Fig. S5A, S5B). Quantification of the numbers of neurons exhibiting calcium transients over the 1 minute time course showed no significant difference between D21 and T21 neurons (Supporting Information Fig. S5B). In addition, under voltage-clamp



Figure 1. Isogenic iPSC model of Down Syndrome generated by reprogramming primary human skin fibroblasts from an adult individual with mosaic Down Syndrome, using a temperature-sensitive Sendai virus. (A): Images of undifferentiated iPSC colonies from two clones (D21C3, T21C5) after three passages; bright-field microphotographs and alkaline phosphatase expression. Further images after immunohistochemistry for pluripotency markers (SSEA4, TRA 1-60, and TRA 1-81). (B): Spontaneous elimination of the temperature sensitive, nonintegrating Sendai virus (Ts-SeV) from iPSC cells through routine passaging. Primary human skin fibroblasts were infected with the Ts-SeV for positive control and were stained with an antibody against the SeV protein HN-IL4.1 alongside the iPSC colonies at the indicated passage numbers (P[n]). The agarose gel shows amplification products after reverse transcriptase polymerase chain reaction (PCR), using SeV (and GAPDH) specific primers (1) D21C3 P5, (2) T21C5 P7, (3) T21C5 P10, (4) D21C3 P10, (5) untransfected fibroblasts, (6) SeV infected fibroblasts P0, (7) SeV infected fibroblasts P0-reverse transcriptase, (8) H<sub>2</sub>O C: Demethylation of endogenous NANOG promoter following reprogramming: bisulfite sequencing analysis of eight CpG dinucleotides in the promoter region of NANOG using genomic DNA isolated from iPSC D21C3 and T21C5, compared to genomic DNA isolated from the primary mosaic DS skin fibroblasts that were used for reprogramming. (D): (Left hand panels): Graphs showing semiquantitative microsatellite PCR analysis for two chromosome 21 (HSA21) markers and for markers from two euploid chromosomes (HSA5, 18) using genomic DNA isolated from iPSC clones. Clones T21C5 and T21C6 are trisomic and Clone D21C3 disomic for HSA21. (Right hand panels): Whole genome microsatellite fingerprint of genomic DNA isolated from iPSC clones, demonstrating that they are isogenic. Abbreviations: Alk Phos, alkaline phosphatase; hiPS clone, human induced pluripotent stem clone; SeV, Sendai Virus.



**Figure 2.** Trisomy 21 causes an increase in  $\beta$ -amyloid containing material in and around neurons generated from iPSCs. **(A)**: Neurons were generated from iPSCs over a 60-day differentiation protocol. Cells were then fixed and stained with an anti-amyloid peptide antibody (6E10), which is reactive to amino acids 1–16 in  $\beta$ -amyloid but detects all APP polypeptide forms that contain the epitope. Nuclei were labeled with Hoechst. Scale bar = 100  $\mu$ m. **(B)**: Quantification of the integrated intensity for the 6E10 stain shows an increase of APP expression in T21 neurons compared to the isogenic D21 neurons. Image capture and quantification were performed using automated multiparametric analysis on the ImageXpress Micro XL (Molecular Devices) wide-field high content imaging system, and data were analyzed using MetaMorph software. Three wells per cell line and a minimum of 6,000 cells per well were analyzed. Student's *t* test, error bars SEM. Visually, T21 neurons appear to also show more 6E10-reactive aggregates (not quantitated). Zoomed-in images for T21C6 and D21C7 are shown at the same size and magnification.

conditions, we identified neuronal sensitivities to GABA and glycine which indicates the cell surface expression of functional GABA<sub>A</sub> and glycine receptors. This was apparent in most cells tested, with no difference noted between T21 and D21 cells (not shown).

To examine early stages of iPSC differentiation an EB protocol was adopted for both hematopoietic and neuronal differentiation, modifying the published method [26]. For hematopoietic EBs (HEBs) 3,000 live cells in single cell suspension were allowed to aggregate in a 96-well. Imaging and analysis of HEBs after 5 days showed that T21 HEBs were significantly larger than the euploid controls (Supporting Information Fig. S6A). This increase in HEB size was caused by an increase in the cell numbers (Supporting Information Fig. S6B), which at this stage is predicted to be early hematopoietic mesoderm precursors. A similar result was obtained with



**Figure 3.** Trisomy 21 results in an increase in size and number of mitochondria in neurons generated from induced pluripotent stem cells (iPSCs). **(A)**: Neurons were generated from iPSCs over a 60-day differentiation protocol. Live cells were then loaded with JC-10 to assess mitochondrial membrane potential. Healthy mitochondria are labeled in red, while green cytoplasmic staining indicates that JC-10 is diffusing out of the mitochondria due to decreased mitochondrial membrane potential. Representative images for each cell line are shown. Image capture and quantification were performed using automated multiparametric analysis on the ImageXpress Micro XL (Molecular Devices) wide-field high content imaging system, and data were analyzed using MetaMorph software. A total of four wells and a minimum of 1,500 cells per cell line were imaged and analyzed. Scale bar = 100  $\mu$ m (identical scale for all images). **(B)**: Quantification of the integrated intensity for the green signal generated by JC-10 shows decreased mitochondrial membrane potential area show that both are increased in T21 neurons. **(D)**: Quantification of the integrated intensity for the green signal generated by JC-10 shows decreased mitochondrial membrane potential in T21 neurons compared to the isogenic D21 neurons. Student's *t* test, error bars SEM.

early T21 mesodermal colonies derived from transchromosomic mouse embryonic stem cells [7]. Although the T21 HEBs gave a higher proportion of CD34+ cells (hematopoietic stem/progenitor lineages) on both days 12 and 18 of further differentiation (not shown), there was no statistically significant difference. By contrast, NPCs derived from NEBs showed a reduction in proliferation rate. The cumulative population doublings of trisomic cells was significantly reduced during the expansion of NPCs (Supporting Information Fig. S6C). Increased cell death is unlikely to be the cause of the observed decrease population cell doubling, because the proportion of nonviable cells in the same counts shows no increase in T21 NPCs (Supporting Information Fig. S6D).

iPSC-derived neurons were analyzed after 60 days of differentiation following the dual SMAD inhibition protocol (mentioned previously, but here minus purmorphamine) that 2082



**Figure 4.** Trisomy 21 causes an increase in DNA damage in neurons generated from induced pluripotent stem cells (iPSCs). **(A):** Neurons were generated from iPSCs over a 60-day differentiation protocol. Cells were then fixed and stained with a  $\gamma$ H2AX antibody to detect DNA double-strand breaks. Nuclei were labeled with Hoechst. Scale bar = 100  $\mu$ m. Enlarged insets for D21C3 and T21C5 double stained with Hoechst and  $\gamma$ H2AX antibody are shown as examples below main images. **(B):** The number of  $\gamma$ H2AX puncta per cell is significantly increased in T21 neurons compared to the isogenic D21 neurons. Image capture and quantification were performed using automated multiparametric analysis on the ImageXpress Micro XL (Molecular Devices) wide-field high content imaging system, and data were analyzed using MetaMorph software. Three wells per cell line and a minimum of 6,000 cells per well were analyzed. Student's *t* test, error bars SEM.

generates multiple classes of projection neurons from different cortical layers [25]. We observed the typical morphology of neurogenic cortical rosettes as published [27] and confirmed that after 60 days neuronal differentiation, >95% of cells were Tuj1+ (not shown). As this protocol generated 100% excitatory glutamatergic neurons [25, 27], and as no differences in the composition of cortical layer subpopulations were observed between DS and normal human iPSCs [15], we think it is unlikely that difference in cell type profiles would be responsible for the differences between T21 and D21 observed in our results, although we cannot fully rule out this possibility. Immunostaining of fixed neurons with an antibody (6E10) raised against the epitopes in the A $\beta$ -peptide, but reactive to all proteolytic fragments of the amyloid precursor protein that contain this epitope, revealed an increase in total amyloid staining in trisomic neurons compared to isogenic euploid controls (Fig. 2A, 2B). This demonstrates that increased amyloid production can be successfully modeled in these cells. Trisomic neurons also appear to show an increase in size and number of 6E10-reactive discreet punctiform aggregates (not quantified, Fig. 2B zoom). Our staining does not permit us to conclude if these aggregates are intracellular or extracellular.

To assess mitochondrial membrane potential in neurons, live cells were labeled with JC-10 (Fig. 3A). In healthy cells JC-10 selectively accumulates in the mitochondria and forms aggregates with a characteristic fluorescent emission at 590 nm (orange/red). If mitochondrial membrane potential is decreased (due to damaged/unhealthy cells) JC-10 monomers are formed, which are released into the cytoplasm, resulting in a shift to green emission at 525 nm. An increase in both the size and number of mitochondria were observed in the trisomic neurons (Fig. 3B, 3C), consistent with a previous study in primary T21 neurons which showed "generalized perturbations" in T21 mitochondrial structure and function, including a more fragmented mitochondrial network [9]. Trisomic neurons also showed a decreased mitochondrial membrane potential, as evidenced by the increase in green cytoplasmic staining with JC-10 (Fig. 3D).

Having shown that T21 neurons have a deficit in mitochondrial function similar to primary human T21 neurons in vitro, we anticipate that reactive oxygen species (ROS) production is increased in T21 neurons. Increased ROS leads to increased DNA damage, as measured by the proportion of  $\gamma$ H2AX foci, an in vitro marker of ageing, shown increased in primary fibroblasts from old, compared to young humans [28], and in primary neurons from old, compared to young mice [29]. We assessed the number of  $\gamma$ H2AX foci (Fig. 4A). Fully automated quantification of approximately 18,000 cells per cell line showed a significantly increased number of  $\gamma$ H2AX puncta per cell in T21 neurons (Fig. 4B).

## DISCUSSION

In conclusion, we report a first nonintegration-reprogrammed isogenic and high genomic fidelity iPSC model from an adult with mosaic DS. The model reproduces several differentiation, ageing, and neurodegeneration-related cellular phenotypes associated with DS pathology and attributable solely to T21 as a cause.

Particularly intriguing are two observations (Figs. 3, 4) that open a whole set of new interesting mechanistic questions. Increased number of mitochondria in neurons could be related to increased mitochondrial fragmentation observed in primary DS cortical neurons in culture [9]. On the other hand, it is possible that T21 mitochondria in DS neurons, which are high consumers of energy exclusively derived from oxidative metabolism, are hypofunctional (as has been observed in primary DS cortical neurons in culture [9]), and the demand for more energy increases mitochondrial biogenesis. These hypotheses remain to be tested. Increased number of DNA double-strand breaks in T21 neurons (Fig. 4) could be further exploited as a cellular marker of accelerated ageing observed in DS [10, 30]. Alternatively, more genomic instability in the nuclei of postmitotic T21 neurons (such as transposition events) [31] could also explain this observation.

Currently, several interdisciplinary consortia have been organized to study DS genetics and cellular models integrated with the assessment of the adult population with DS for neurocognitive function, age-related decline, presence or absence of dementia and other comorbidities (e.g., see http://www. ucl.ac.uk/london-down-syndrome-consortium, http://www.psychiatry.cam.ac.uk/ciddrg/research/dementia-in-downs-syn-

drome-dids/). It is therefore important to verify that cellular phenotypes under-pinning DS pathology can also be reproduced in iPSCs derived from an adult individual with DS, as this had not been reported so far.

Up to 75% of constitutionally T21 concepti spontaneously die in utero [10, 32] suggesting that in random allelic variation, the presence of a third copy of HSA21 has a 75% probability to cause severe phenotypes that are normally missed. In constitutional mosaicism, T21 with an otherwise deleterious genotype could be rescued by a significant (>50%) presence of normal (D21) cells, which results in varying intensity of clinical DS defects, often not correlating with the percentage of trisomic cells in tissues. This presents with a theoretical (but so far never explored) rationale for T21/D21 cells derived from a constitutionally mosaic DS individual to show more contrasting differences in cellular phenotypes, than comparisons between cells of liveborn 100% trisomic individuals. Such phenotypes are more likely to be robust, reproducible, and therefore more amenable to developing into high throughput screening assays.

#### ACKNOWLEDGMENTS

This work was supported by the project grants from the Kay Kendall Leukaemia Fund (KKL632), and Fondation Jerome Lejeune (2011B/960), by The Wellcome Trust "LonDownS Consortium" Strategic Funding Award (098330/Z/12/Z), and the Lee Kong Chian School of Medicine, Nanyang Technological University-Singapore start-up funding grant M4230024 to D.N., by the "AnEUploidy Consorium" grant from Framework Programme 6 from the EU Commission to D.N. and S.E.A., as well as SNF 144082 and ERC 249968 grants to S.E.A. We also thank Barts and The London Charity and the grant 520/1489: "Development of a National Centre for Bowel Research and Surgical Innovation (NCBRSI)" for purchase of high content imaging equipment. Galliera Genetic Bank as member of the Telethon Network of Genetic Biobanks (Telethon project GTB12001) provided us with specimens. We thank Li Pin for help in setting up the iPSC lab at LKCMedicine in Singapore. We thank Gary Warnes for help with the fluorescence activated cell sorting analysis, and Dominique Bonnet, Silvia Marino, and the BSU Whitechapel for help in using NOD/SCID mice. N.F. is currently affiliated with Dept. of Opthalmology, Keio University School of Medicine, Tokyo, Japan. We dedicate this paper to Prof. Franca Dagna-Bricarelli, our colleague and coauthor who sadly passed away during revision of this manuscript. Her dedicated work in human genetics made all this possible and will remain inspiration to all of us.

### AUTHOR CONTRIBUTIONS

A.M. and J.G.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; A.L.: conception and design, collection and assembly of data, data analysis and interpretation, and manuscript writing; C.C.: conception and design, collection and assembly of data, and data analysis and interpretation; E.S., S.G., and R.A.: collection of data; F.S.-B., P.G., S.H., M.M., D.B., and D.S.-C.: collection of data and data analysis and interpretation; S.L.: data analysis and interpretation; C.Ba. and F.D.-B: provision of study material or patients; N.F. and M.H.: provision of study material; T.S: assembly of data and data analysis and interpretation; C.Bi.: collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; S.A.: financial support, data analysis and interpretation, manuscript writing, and final approval of manuscript; D.N.: conception and design, financial support, collection and assembly of data, data analy-

sis and interpretation, manuscript writing, and final approval of manuscript.

# DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest

#### REFERENCES

**1** Epstein CJ. 2001 William Allan Award Address. From Down syndrome to the "human" in "human genetics". Am J Hum Genet 2002;70:300–313.

**2** Antonarakis SE, Lyle R, Dermitzakis ET, et al. Chromosome 21 and down syndrome: From genomics to pathophysiology. Nat Rev Genet 2004;5:725–738.

**3** Bahn S, Mimmack M, Ryan M et al. Neuronal target genes of the neuronrestrictive silencer factor in neurospheres derived from fetuses with Down's syndrome: A gene expression study. Lancet 2002;359: 310–315.

**4** Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995;378:776–779.

**5** Canzonetta C, Mulligan C, Deutsch S et al. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am J Hum Genet 2008;83:388–400.

**6** Cataldo AM, Mathews PM, Boiteau AB et al. Down syndrome fibroblast model of Alzheimer-related endosome pathology: Accelerated endocytosis promotes late endocytic defects. Am J Pathol 2008;173:370–384.

**7** De Vita S, Canzonetta C, Mulligan C et al. Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome. Oncogene 2010;29:6102–6114.

8 Delom F, Burt E, Hoischen A et al. Transchromosomic cell model of Down syndrome shows aberrant migration, adhesion and proteome response to extracellular matrix. Proteome Sci 2009;7:31.

**9** Helguera P, Seiglie J, Rodriguez J et al. Adaptive downregulation of mitochondrial function in down syndrome. Cell Metab 2013;17:132–140.

**10** Nizetic D, Groet J. Tumorigenesis in Down's syndrome: Big lessons from a small chromosome. Nat Rev Cancer 2012;12:721–732.

**11** Roper RJ, Baxter LL, Saran NG et al. Defective cerebellar response to mitogenic

Hedgehog signaling in Down's syndrome mice. Proc Natl Acad Sci USA 2006;103: 1452–1456.

**12** Wang Y, Mulligan C, Denyer G et al. Quantitative proteomics characterization of a mouse embryonic stem cell model of Down syndrome. Mol Cell Proteom 2009;8:585– 595.

**13** Jiang J, Jing Y, Cost GJ et al. Translating dosage compensation to trisomy 21. Nature 2013;500:296–300.

**14** Maclean GA, Menne TF, Guo G et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci USA 2012;109:17567–17572.

**15** Shi Y, Kirwan P, Smith J et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci Transl Med 2012;4:124ra129.

**16** Park IH, Arora N, Huo H et al. Diseasespecific induced pluripotent stem cells. Cell 2008;134:877–886.

**17** Hibaoui Y, Grad I, Letourneau A et al. Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21. EMBO Mol Med 2014;6:259–277.

**18** Briggs JA, Sun J, Shepherd J et al. Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology. Stem Cells 2013;31:467–478.

**19** Weick JP, Held DL, Bonadurer GF, 3rd, et al. Deficits in human trisomy 21 iPSCs and neurons. Proc Natl Acad Sci USA 2013;110: 9962–9967.

**20** Chou ST, Byrska-Bishop M, Tober JM et al. Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci USA 2012;109:17573–17578.

**21** Li LB, Chang KH, Wang PR et al. Trisomy correction in down syndrome induced pluripotent stem cells. Cell Stem Cell 2012;11: 615–619.

22 Ban H, Nishishita N, Fusaki N et al. Efficient generation of transgene-free human

induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci USA 2011;108:14234– 14239.

**23** Hussein SM, Batada NN, Vuoristo S et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011;471:58–62.

**24** Luong MX, Auerbach J, Crook JM et al. A call for standardized naming and reporting of human ESC and iPSC lines. Cell Stem Cell 2011;8:357–359.

**25** Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc 2012;7:1836–1846.

**26** Ng ES, Davis RP, Hatzistavrou T et al. Directed differentiation of human embryonic stem cells as spin embryoid bodies and a description of the hematopoietic blast colony forming assay. Curr Protoc Stem Cell Biol 2008;Chapter 1:Unit 1D 3.

**27** Shi Y, Kirwan P, Smith J et al. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat Neurosci 2012;15:477–486, S471.

**28** Miller JD, Ganat YM, Kishinevsky S et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 2013;13:691–705.

**29** Jurk D, Wang C, Miwa S et al. Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. Aging Cell 2012;11:996– 1004.

**30** Adorno M, Sikandar S, Mitra SS et al. Usp16 contributes to somatic stem-cell defects in Down's syndrome. Nature 2013; 501:380–384.

**31** Erwin JA, Marchetto MC, Gage FH. Mobile DNA elements in the generation of diversity and complexity in the brain. Nat Rev Neurosci 2014;15:497–506.

**32** Spencer K. What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester? Prenat Diagn 2001; 21:788–789.

See www.StemCells.com for supporting information available online.